**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 53451

**Manuscript Type:** SYSTEMATIC REVIEW

**Carrier frequency of HLA-DQB1\*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening**

Poddighe D *et al.* Epidemiological importance of HLA-DQB1\*02 carrier status in CD patients

Dimitri Poddighe, Chiara Rebuffi, Annalisa De Silvestri, Cristina Capittini

**Dimitri Poddighe,** Department of Medicine, School of Medicine, Nazarbayev University, Nur-Sultan 010000, Kazakhstan

**Chiara Rebuffi,** Grant Office and Scientific Documentation Center, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy

**Annalisa De Silvestri, Cristina Capittini,** Scientific Direction, Clinical Epidemiology and Biometric Unit, Fondazione IRCCS Policlinico San Matteo, Pavia 27100, Italy

**Cristina Capittini,** Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia 27100, Italy

**Author contributions:** Poddighe D conceived this manuscript; Poddighe D and Capittini C wrote this manuscript; Rebuffi C, Poddighe D, Capittini C and De Silvestri A all contributed and performed the systematic search and literature analysis.

**Supported by** the Nazarbayev University Faculty Development Competitive Research Grant 2020-2022, No. 240919FD3912.

**Corresponding author: Dimitri Poddighe, MD, MSc, Assistant Professor, Medical Specialist in Pediatrics,** Department of Medicine, School of Medicine, Nazarbayev University, Kerei-Zhanibek Street 5/1, Nur-Sultan 010000, Kazakhstan. dimitri.poddighe@nu.edu.kz

**Received:** December 19, 2019

**Revised:** March 10, 2020

**Accepted:** March 22, 2020

**Published online:**

**Abstract**

BACKGROUND

Celiac disease (CD) is an immune-mediated disorder, in which the HLA immunogenetic background (DQ2 and DQ8 heterodimers) and environmental trigger (gluten) are well established. Indeed, both factors are necessary – but not sufficient – to develop CD. However, it is very likely that CD is underdiagnosed in both developing and developed countries, due to several aspects, including the fact that a lot of patients present mild and/or atypical symptoms, without the presence of any recognized risk factors. Therefore, the possibility and feasibility of widened screening strategies to identify CD patients is debated.

AIM

To provide further evidence of the main epidemiological importance of HLA-DQB1\*02 allele in the population of CD patients.

METHODS

We performed a systematic search in PubMed, EMBASE, Cochrane, Web of Science and Scopus databases, in order to produce a systematic review assessing the carrier frequency of HLA-DQB1\*02 allele in the celiac population. Following the PRISMA guidelines, we retrieved all the original articles describing CD patients’ HLA-DQB1 genotype in such a way that could allow to assess the HLA-DQB1\*02 carrier frequency among CD patients, along with the evidence of the appropriate diagnostic work-up to achieve a correct and final diagnosis of CD.

RESULTS

The final output of this systematic search in the medical literature consisted of 38 studies providing the appropriate HLA-DQB1 genotype information of the respective CD population. According to this systematic review, including a pool of 4945 HLA-DQ genotyped CD patients, the HLA-DQB1\*02 carrier frequency was 94.94%, meaning that only 5.06% of CD patients were completely lacking this allelic variant. Interestingly, if we consider only the studies whereby the prevalence of CD patients along with type 1 diabetes mellitus was supposed or clearly established to be very low, the frequency of non-HLA-DQB1\*02 carriers among CD patients dropped up to 3.65%.

CONCLUSION

Such a high carrier frequency of the HLA-DQB1\*02 allelic variant (which is > 95%-96% in CD patients without risk factors, like type 1 diabetes mellitus comorbidity) might be exploited to consider a cost-effective and widened screening approach: if a sustainable strategy could be implemented through a low-cost targeted genetic test to detect the individual presence of HLA-DQB1\*02 allele, an appropriate algorithm for serological screening in individuals resulting to be genetically predisposed to CD might be considered.

**Key words:** Celiac disease; Children; HLA-DQB1\*02; DQ2 heterodimer; Screening; Systematic review

Poddighe D, Rebuffi C, De Silvestri A, Capittini C. Carrier frequency of HLA-DQB1\*02 allele in patients affected with celiac disease: A systematic review assessing the potential rationale of a targeted allelic genotyping as a first-line screening. *World J Gastroenterol* 2020; In press

**Core tip:** It is well known that HLA-DQ genotyping is useful to assess the individual susceptibility to celiac disease (CD) with very high - if not absolute – discriminatory power: Indeed, it is very unlikely that individuals who do not carry specific HLA-DQ alleles coding MHC-DQ2 and MHC-DQ8 heterodimers, may develop CD. Here, we aim at providing further evidence of the specific epidemiological importance of HLA-DQB1\*02 allele in the population of CD patients. Briefly, based on 38 original articles that we included in this systematic review (which provided a pool of 4945 HLA-DQ genotyped CD patients, overall), we could find a very high carrier frequency of the HLA-DQB1\*02 allelic variant. Indeed, > 95%-96% of CD patients resulted to carry at least one copy of the HLA-DQB1\*02 allele. This knowledge might be exploited to consider a cost-effective and widened screening approach: If a sustainable strategy could be implemented through a low-cost targeted genetic test for CD, an appropriate algorithm for serological screening in individuals resulting to be genetically predisposed to CD, might be considered.

**INTRODUCTION**

Celiac disease (CD) is a systemic autoimmune disease triggered by the dietary intake of gluten in a minority of HLA genetically predisposed individuals[1]. The world prevalence of CD in the general population is estimated to be around 1%, despite some geographical and ethnic variations. Recent epidemiological analyses suggested that the CD prevalence in children may be even greater than 1%[2-4].

In the landscape of non-communicable autoimmune diseases, CD presents some peculiar etiological aspects. As mentioned, the necessary environmental trigger for CD is well-known, namely the dietary exposure to gluten, which can lead to CD in a minority of all individuals expressing DQ2 and/or DQ8 heterodimers. Respectively, these antigen-presenting molecules are encoded by the specific alleles DQA1\*0501-DQB1\*02 and DQA1\*0301-DQB1\*0302. In North America and Europe, the individuals with such an immunogenetic predisposition to CD are 30%-40% of the general population, but only a minority of them (around 3%) will actually develop CD during life, despite a comparable exposure to gluten foods[1,2].

However, CD is under-diagnosed, even in developed countries. Indeed, according to the so-called “celiac iceberg” epidemiological model, only a minority of cases (the emerged tip of the iceberg) are clinically well-evident, whereas most part (the iceberg mass under the water surface) have atypical and/or pauci-symptomatic clinical presentations, making CD diagnosis be under-considered and/or significantly delayed[2,5]. Case-finding screening strategies helped to diagnose patients with some clinical and family risk factors, but the numerical impact of this approach in terms of number of CD diagnoses, is quite limited. Indeed, most CD patients do not have any of these specific risk factors[6,7]. Moreover, the onset age of CD is extremely variable, which means that the serological screening should be periodically repeated in at-risk individuals[8].

Therefore, the debate about the opportunity to implement universal and/or widened screening strategies for CD is still open, especially in children, who may experience worse consequences than adults in case of missed or delayed CD diagnosis, due to their longer life expectancy and disease onset during the growth process[6,8-11].

Of course, it is not sustainable to propose a universal CD serological screening; however, the identification of HLA genetically predisposed individuals through a cheap analytic method could exclude that larger part of individuals, who will never develop CD. Through this systematic review, we assessed the percentage of CD patients who are carriers of at least one copy of the HLA-DQB1\*02 allele, specifically.

**MATERIALS AND METHODS**

***Protocol***

This systematic review was performed according to the PRISMA guidelines, as described in Figure 1, which shows the complete PRISMA flow diagram. Through this systematic review, we aimed at evaluating the carrier frequency of the specific allelic variant HLA-DQB1\*02 (coding the β chain of DQ2 heterodimer) in the population of patients diagnosed with CD.

***Search strategy***

We performed a systematic search in PubMed, EMBASE, Web of Science, Scopus and Cochrane databases, by retrieving all original articles (case series, case–control, cross-sectional, and retrospective cohort studies) describing CD patients’ HLA-DQB1 genotype in detail. We searched all English, French, Spanish, Italian, German, Portuguese articles published up to September 2019.

In detail, an expert librarian performed the following searches in the following medical databases: (1) PubMed: ("celiac disease"[Mesh] OR "celiac disease" OR “coeliac disease” OR CD) AND ("HLA-DQ Antigens" [MeSH] OR "HLA-DQB1" OR "HLA-DQ2" OR "HLA-DQB1\*02") AND ("alleles"[MeSH] OR allel\* OR "Genes"[MeSH] OR gene OR genes OR variant\* OR type\* OR genotype[Mesh] OR genotyp\*); (2) EMBASE: ('celiac disease'/exp OR 'celiac disease':ti,ab OR 'coeliac disease':ti,ab OR CD:ti,ab) AND ('HLA DQ antigen'/exp OR 'HLA-DQB1':ti,ab OR 'HLA-DQ2:ti,ab OR 'HLA-DQB1\*02':ti,ab) AND ('allele'/exp OR allel\*:ti,ab OR 'Gene'/exp OR gene:ti,ab OR genes:ti,ab OR variant\*:ti,ab OR type\*:ti,ab OR 'genotype'/exp OR genotyp\*:ti,ab) AND [embase]/lim; (3) Web of Science: TS= ("celiac disease" OR “coeliac disease” OR CD) AND ("HLA-DQ Antigen\*" OR "HLA-DQB1" OR "HLA-DQ2" OR "HLA-DQB1\*02") AND (allel\* OR gene OR genes OR variant\* OR type\* OR genotyp\*); (4) Scopus: ("celiac disease" OR “coeliac disease” OR CD) AND ("HLA-DQ Antigen\*" OR "HLA-DQB1" OR "HLA-DQ2" OR "HLA-DQB1\*02") AND (allel\* OR gene OR genes OR variant\* OR type\* OR genotyp\*): ti,ab; and (5) Cochrane: ("celiac disease"[Mesh] OR "celiac disease":ti,ab,kw OR “coeliac disease”:ti,ab,kw OR CD:ti,ab,kw) AND ("HLA-DQ Antigens" [MeSH] OR "HLA-DQB1":ti,ab,kw OR "HLA-DQ2":ti,ab,kw OR "HLA-DQB1\*02":ti,ab,kw) AND ("alleles"[MeSH] OR allel\*:ti,ab,kw OR "Genes"[MeSH] OR gene:ti,ab,kw OR genes:ti,ab,kw OR variant\*:ti,ab,kw OR type\*:ti,ab,kw OR genotype[Mesh] OR genotyp\*:ti,ab,kw).

***Data extraction***

After a critical reading of the articles, two investigators independently performed data extraction according to the following inclusion criteria: any original articles in which CD patients’ HLA-DQB1 genotype was described in such a way and detail that the number of HLA-DQB1\*02 carriers could be clearly defined within the total of the respective CD population. Only articles defining CD cases based on the typical histopathological findings, in addition to the specific serology, were considered. Most of them referred to specific diagnostic criteria, such as those set by Meeuwisse[12], Walker-Smith *et al*[13] and Husby *et al*[14], according to the study period. In detail, the following items were extracted from each study: first author's last name, publication date, country of origin, numbers of male/female patients, patient’s age range and HLA-DQB1 genotype (in terms of HLA-DQB1\*02 carriers or not).

**RESULTS**

***Study selection***

The process of literature screening and selection according to the PRISMA guidelines, is summarized in Figure 1. As a result, 112 full-text articles have been identified as potentially eligible for this systematic review, because those included some information on the HLA genotype of the respective CD study population. However, as summarized in Table 1, only 38 studies were finally included in the present systematic review, because they only provided enough details of the HLA-DQB1 genotype to appropriately assess the HLA-DQB1\*02 carrier frequency among CD patients, along with the evidence of the appropriate diagnostic work-up to achieve a correct and final diagnosis of CD[15-56].

Indeed, as already mentioned, the aim of this systematic review is to assess the frequency of the HLA-DQB1\*02 carriers (at least one copy) in the population of CD patients, including both children and adults. This final research output resulted from the analysis of all retrieved full-length original articles describing the HLA-DQ genotype in patients with CD with appropriate resolution and details. Indeed, in order to be considered, the paper had to provide information about the complete HLA-DQB1 genotype for each patient or group of patients affected with CD; or enough information to certainly establish how many CD patients were carriers of at least one copy of the HLA-DQB1\*02 allele. Therefore, the original articles reporting only the HLA-DQ allelic frequencies in the study populations were necessarily excluded, since the endpoint is not to assess how frequent is HLA-DQB1\*02 in the CD population, but how many of them are carrier of at least one copy of this specific allelic variant.

After this qualitative selection of papers including the required information about the HLA-DQ genotype, we excluded all researches including a genetically biased CD population, namely those with a CD population resulting from a preliminary HLA genetic screening. Moreover, according to our main focus on those individuals that are not considered to be at risk in the current clinical recommendations of CD case-finding screening strategies, we have included as far as possible only those articles in which the CD study population was not pre-selected through a specific (autoimmune) comorbidity and, in particular, type 1 diabetes mellitus (DM1). Indeed, it is clearly established that patients with DM1 must be followed-up for the potential CD onset, due to the common background of HLA-DQ genetic predisposition, whereas our analysis aims to provide a preliminary information that could be useful to design a potential strategy of mass screening for that majority of CD patients without any comorbidity, who are actually more likely to have a delayed diagnosis or remain undiagnosed.

***Study quality***

The quality of selected studies in terms of laboratory methods, methods description, statistical methodology and clinical features was assessed according to PRISMA standards and resulted to be appropriate.

***Carriers frequency of the HLA-DQB1\*02 carriers in the CD population***

Based on the 38 selected articles (Table 1), a total of 5065 patients affected with CD were included in this systematic review, but the HLA-DQ genotyping was not available for 120 of them. Among 4945 HLA-DQ genotyped CD patients, 4695 resulted to be carriers of at least one copy of the HLA-DQB1\*02 allele, whereas 250 carried different allelic variants at both HLA-DQB1 loci (HLA-DQB1\*0302 or others). Therefore, the HLA-DQB1\*02 carrier frequency resulted to be 94.94%, meaning that only 5.06% of CD population was completely lacking this allelic variant.

If only the CD pediatric population (*n* = 2710) is considered, similar figures are obtained: 94.69% of CD children carry the HLA-DQB1\*02 allele, whereas only 5.31% is lacking a copy of this allelic variant.

Finally, if we consider only the studies whereby the prevalence of CD patients along with DM1 was supposed or clearly established to be very low (< 3%), the frequency of non-HLA-DQB1\*02 carriers among CD patients dropped up to 3.65%.

**DISCUSSION**

Through this systematic review, we demonstrate that around 95% of all patients affected with CD carry the HLA-DQB1\*02 allele, at least in one copy. Importantly, this figure raises up to > 96%, if only CD patients without DM1 are considered. This finding may contribute to the implementation of a cost-effective and preliminary genetic test to assess the existence of CD predisposition, through the targeted qualitative analysis of HLA-DQB1\*02 allelic presence. This knowledge might help to optimize the use of the serological analyses for CD and, at the same time, extend the screening possibility, at least in the pediatric population.

As described in the introduction, the HLA-DQ genetic background is fundamental to determine the predisposition to develop CD. The coupled alleles DQA1\*0501-DQB1\*02 and DQA1\*0301-DQB1\*0302 respectively code the class II MHC heterodimers DQ2 and DQ8, which have been demonstrated to be expressed in almost all patients affected with CD. Indeed, several studies confirmed the very high negative predictive value associated with the absence of any genotypes coding MHC-DQ2 and/or -DQ8[1,2]. Practically, this specific knowledge can be applied to those patients with a suspect of CD, whenever the histopathological findings are not straightforward or the presence of concomitant diseases impairs the reliability of the serological tests (*e.g.,* IgA deficiency, Common Variable Immunodeficiency, *et al*). Therefore, the high-resolution analysis of HLA-DQ loci resulted to be particularly useful to refine and/or complete the diagnostic work-up for CD in some complex clinical cases, where the absence or presence of any heterodimers can respectively rule out or support the final diagnosis of CD. Of course, the routine use of this expensive HLA analysis is completely inappropriate, because it can only assess the predisposition to develop CD (and not the disease). Indeed, large part of the general population (around 30%-40%, according to the ethnic variability) possesses the appropriate HLA background to potentially develop CD[14].

Several studies investigated the relationship between HLA-DQ genotype of CD patients and some clinical characteristics, histopathological features, age of disease onset and even the risk to develop CD[21,25,46,52]. In this specific regard, several original articles reported a risk gradient for CD according to the particular HLA-DQ genotype: people with DQ2 homozygosity and DQ2/DQ8 heterozygosity resulted to be have the highest risk and, importantly, a comparable risk of CD development was present in individuals carrying a double dose of HLA-DQB1\*02 alleles, no matter the paired HLA-DQA1 alleles[27,43,57]. Recently, two meta-analysis by our group supported this finding (OR > 5, compared to the general population) and further emphasized that also a single “dose” of HLA-DQB1\*02 is associated with a relatively high risk (OR ≈ 4), as regards pediatric CD[58-59]. In detail, we described that the HLA-DQB1\*02 allele was present in 90%-95% of pediatric CD patients[58] and, in our clinical monocentric clinical experience, we found > 95% of CD children who were carriers of at least one copy of HLA-DQB1\*02 allele[50]. Therefore, we speculated that such a knowledge might be potentially used to consider the implementation of a widened screening strategy for CD in children, through a qualitative analysis targeting the HLA-DQB1\*02 allele exclusively as a first step, followed by the serological screening, to be applied to positive individuals only[11,50].

In order to further consider this potential idea, we decided to quantitively assess the actual presence of at least one copy of this allele among the CD population and, thus, understand how many patients would be lost if only the HLA-DQB1\*02 positive individuals should undergo the serological screening for CD. If the loss of potential CD patients (those negative for HLA-DQB1\*02 and, basically, carrying the DQ8 heterodimer only) could result acceptably low, then this approach might prevent the request (and the periodical re-testing) of any serological screening to most children. Anyway, the serological screening could be performed anytime in all those HLA-DQB1\*02 negative patients developing symptoms consistent with CD, of course.

The present systematic review estimated that only 5% of the general CD population (including both adults and children) is devoid of HLA-DQB1\*02 allele at all. If we could consider a mass screening looking for the carrier status of HLA-DQB1\*02 only, we may identify 95% of CD predisposed patients and, concomitantly, rule out (with no more than a 5% error) the lifetime risk of disease in 60%-70% of the general population: these non-predisposed individuals should never receive the serological screening, unless any consistent clinical symptoms appear at some point of the existence without any other explanation.

Actually, according to this last consideration, that error may be even over-estimated. Indeed, if we consider only the articles describing cohorts of CD patients with a low prevalence of concomitant DM1 (Table 1), the percentage of non-HLA-DQB1\*02 carriers decrease to 3.65%. Although the genetic predisposition to DM1 relies on both DQ2 and DQ8 heterodimers as well, this disease-genotype association for DM1 is less strong than in CD and, importantly, the DQ8 role and frequency resulted to be more relevant in patients with DM1, as evidenced by several studies. In a pediatric study from northwestern Mexico, including both CD and DM1 patients, Mejía-León *et al*[60] showed that the HLA-DQ8 combinations with DQ2 or one of its alleles conferred the highest risk for the combination of both diseases. Smigoc Schweiger *et al*[61] reported that DQ2 and DQ8 were present in 52% and 76% of DM1 patients in their Slovenian cohort, respectively. Mitchell *et al*[62] described the DQ2/DQ8 analysis of 176 Scottish children with DM1: at least 50%-55% were DQ8 carriers and, importantly, it was not associated with DQ2 in around 20% of patients. In summary, the frequency of the homozygous HLA-DQ8 genotype and, in general, heterozygous HLA-DQ8 without any copy of HLA-DQB1\*02 is expected to be higher in DM1 patients than in patients with CD.

Moreover, some studies included in this systematic review paired patients with CD only and cohorts of patients affected with DM1 and DM1+CD. In the study by Dezsofi *et al*[26], DQ2 negative patients affected with CD only were as few as 4%, whereas DQ2 negative patients were 10.6% in CD patients affected with DM1, and 35% in patients with DM1 only. Viken *et al*[44] adopted a similar - but larger - study design to investigate the HLA class II alleles in Norwegian patients with coexisting DM1 and CD. Whereas DQ2 negative (all DQ8 homo- or heterozygous) patients do not exceed 5% in the CD-only cohort, they reach 30% in CD+DM1 patients and exceed this percentage in patients with DM1 only. In the study by Kauma *et al*[48], two groups of CD patients were considered (namely, CD index cases and siblings affected with CD) and the number of patients with concomitant DM1 was quite different (1/66 and 4/66, respectively): interestingly, the frequency of non-HLA-DQB1\*02 carriers was much more prevalent in the latter group (10.6% *vs* 3%), due to the higher HLA-DQB1\*0302 (DQ8) allelic frequency in the DM1 subgroups of CD patients.

This systematic review is limited by the fact that only studies providing enough and appropriate information about the HLA-DQB1 genotype for each patient or groups of patients, could be included in our analyses. However, genetic pre-selection biases were carefully considered and, thus, avoided, in order to provide reliable findings for our analysis purposes.

A potential HLA-DQB1\*02-targeted screening approach would be addressed to all those people that does not fall into the ESPGHAN groups at risk for CD (and, thus, receiving a periodical serology screening anyway), because this case-finding strategy leaves the majority of asymptomatic or pauci-symptomatic CD patients undiagnosed[63,64]. Of course, it is not currently sustainable to propose a periodical serology screening for CD to the general population, even if limited to children, who may be more vulnerable to the negative long-term consequences of undiagnosed or belatedly diagnosed CD[6]. If the HLA-DQB1\*02 qualitative (present/not present) screening could be feasible after a rigorous economical and ethical assessment, it would allow to identify almost all CD-predisposed children, who should be around 30-40% of the general pediatric population. Therefore, 60-70% should not be eligible to receive the serology screening anymore, and a (periodic) serological test could be proposed to the HLA-DQB1\*02 predisposed children only. At the end, this approach might also lead to some savings on the costs currently allocated to the CD serological screening, if we consider that these tests are often over-requested by patients and practitioners[64-66].

The cost of CD diagnostic testing variably affects both patients and the healthcare system. The gold standard for diagnosis uses a combination of methods, which usually begins with a serological testing that includes immunoglobulin A (IgA) and tissue transglutaminase (TTG) IgA[67]. A study (including 250 healthy children) from Europe reported that screening with serum TTG cost €5000 annually, rising to €11250 if anti-endomysium (EMA) testing was additionally performed on every child. Therefore, in Europe, each ELISA-based TTG test costs approximately 20€, without considering the total IgA measurement[68]. Identifying that majority of children who do not need the serological screening because they are not genetically predisposed to CD, might result in a significant reduction of costs sustained for CD serology. According to the findings of this systematic review, < 5% of CD-predisposed children may be lost through this screening approach and, if a patient should develop symptoms consistent with CD at any time during own life, the serology test could be performed anyway on a clinical basis.

Low-cost molecular methods for targeted and qualitative HLA-typing can be at the horizon. For instance, Verma *et al*[69] recently proposed a rapid HLA-DQ typing method to identify subjects genetically susceptible to CD by performing a PCR through a kit containing all four HLA-DQ target alleles only. The cost of such an HLA-DQ genotyping was about €15 and, probably, may be further reduced by using reagents to detect the HLA-DQB1\*02 allele only. Children would receive this test only one time and 30%-40% of them (those with positive results) could be identified as CD-predisposed and, then, eligible to serology screening at specific time points to be established.

In conclusion, a cost-effective and widened screening approach may be very helpful in both developed and developing countries, if a sustainable strategy could be implemented through a low-cost targeted genetic test for the HLA-DQB1\*02 allelic presence, along with appropriate algorithms for serological screening in the individuals with this specific HLA-DQ predisposition to CD. Of course, specific pharmacoeconomic studies and ethical considerations would be needed, before a specific strategy can be proposed.

**ARTICLE HIGHLIGHTS**

***Research background***

Celiac disease (CD) is an immune-mediated disorder in which the HLA immunogenetic background (DQ2 and DQ8 heterodimers) is well known. This genetic factor is necessary – but not sufficient – to develop CD. Basically, almost 100% of CD patients are carriers of the aforementioned HLA-DQ background and several studies emphasized the main role of the HLA-DQB1\*02 allele in such a genetic predisposition.

***Research motivation***

CD is underdiagnosed in both developing and developed countries, due to several aspects: indeed, many patients present mild and/or atypical symptoms, without the presence of any recognized risk factors. Therefore, the possibility and feasibility of widened screening strategies to identify CD patients is still debated and this study might provide some additional insights, in order to find novel screening strategies.

***Research objectives***

Our aim was to define and assess the carrier frequency of the specific allelic variant HLA-DQB1\*02 (coding the β chain of DQ2 heterodimer) in the population of patients diagnosed with CD.

***Research methods***

In order to achieve our aim, we performed a systematic review, according to the PRISMA guidelines, by retrieving all original articles (case series, case–control, cross-sectional, and retrospective cohort studies) describing CD patients’ HLA-DQB1 genotype in detail. Any original articles in which CD patients’ HLA-DQB1 genotype was described in such a way and detail that the number of HLA-DQB1\*02 carriers could be clearly defined (within the total of the respective CD population), was considered.

***Research results***

As a result of our literature search, 38 studies were finally included in the present systematic review, since those provided details of the HLA-DQB1 genotype in such a way that could allow to assess the HLA-DQB1\*02 carrier frequency among CD patients. Among 4945 HLA-DQ genotyped CD patients, the HLA-DQB1\*02 carrier frequency resulted to be 94.94%, meaning that only 5.06% of CD population was completely lacking this allelic variant. If only the CD pediatric population is considered, similar figures are obtained: only 5.31% is lacking a copy of this allelic variant. Finally, if we consider only the studies whereby the prevalence of CD patients also affected with type 1 diabetes mellitus (DM1) was supposed or clearly established to be very low, the frequency of non-HLA-DQB1\*02 carriers among CD patients dropped up to 3.65%.

***Research conclusions***

According to the findings of this systematic review, < 4%-5% of CD-predisposed children may be lost through a preliminary evaluation of the presence/absence of HLA-DQB1\*02 allele, regardless of the presence of other HLA-DQB1 and HLA-DQA1 CD-predisposing alleles.

***Research perspectives***

A cost-effective and widened screening approach may be very helpful in both developed and developing countries, if a sustainable strategy could be implemented through a low-cost targeted genetic test for the HLA-DQB1\*02 allelic presence, along with appropriate algorithms for serological screening in individuals resulting to be genetically predisposed to CD.

**REFERENCES**

1 **Lindfors K**, Ciacci C, Kurppa K, Lundin KEA, Makharia GK, Mearin ML, Murray JA, Verdu EF, Kaukinen K. Coeliac disease. *Nat Rev Dis Primers* 2019; **5**: 3 [PMID: 30631077 DOI: 10.1038/s41572-018-0054-z]

2 **Lebwohl B**, Sanders DS, Green PHR. Coeliac disease. *Lancet* 2018; **391**: 70-81 [PMID: 28760445 DOI: 10.1016/S0140-6736(17)31796-8]

3 **Poddighe D**, Rakhimzhanova M, Marchenko Y, Catassi C. Pediatric Celiac Disease in Central and East Asia: Current Knowledge and Prevalence. *Medicina (Kaunas)* 2019; **55** [PMID: 30642036 DOI: 10.3390/medicina55010011]

4 **Poddighe D**, Turganbekova A, Baymukasheva D, Saduakas Z, Zhanzakova Z, Abdrakhmanova S. Genetic predisposition to celiac disease in Kazakhstan: Potential impact on the clinical practice in Central Asia. *PLoS One* 2020; **15**: e0226546 [PMID: 31895924 DOI: 10.1371/journal.pone.0226546]

5 **Nenna R**, Tiberti C, Petrarca L, Lucantoni F, Mennini M, Luparia RP, Panimolle F, Mastrogiorgio G, Pietropaoli N, Magliocca FM, Bonamico M. The celiac iceberg: characterization of the disease in primary schoolchildren. *J Pediatr Gastroenterol Nutr* 2013; **56**: 416-421 [PMID: 23149808 DOI: 10.1097/MPG.0b013e31827b7f64]

6 **Ludvigsson JF**, Card TR, Kaukinen K, Bai J, Zingone F, Sanders DS, Murray JA. Screening for celiac disease in the general population and in high-risk groups. *United European Gastroenterol J* 2015; **3**: 106-120 [PMID: 25922671 DOI: 10.1177/2050640614561668]

7 **Catassi C**, Lionetti E. Case finding for celiac disease is okay, but is it enough? *J Pediatr Gastroenterol Nutr* 2013; **57**: 415-417 [PMID: 23863326 DOI: 10.1097/MPG.0b013e3182a45676]

8 **Ludvigsson JF**, Murray JA. Epidemiology of Celiac Disease. *Gastroenterol Clin North Am* 2019; **48**: 1-18 [PMID: 30711202 DOI: 10.1016/j.gtc.2018.09.004]

9 **US Preventive Services Task Force.**, Bibbins-Domingo K, Grossman DC, Curry SJ, Barry MJ, Davidson KW, Doubeni CA, Ebell M, Epling JW Jr, Herzstein J, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. *JAMA* 2017; **317**: 1252-1257 [PMID: 28350936 DOI: 10.1001/jama.2017.1462]

10 **Ludvigsson JF**. Mortality and malignancy in celiac disease. *Gastrointest Endosc Clin N Am* 2012; **22**: 705-722 [PMID: 23083988 DOI: 10.1016/j.giec.2012.07.005]

11 **Poddighe D**. Individual screening strategy for pediatric celiac disease. *Eur J Pediatr* 2018; **177**: 1871 [PMID: 30225634 DOI: 10.1007/s00431-018-3251-6]

12 **Meeuwisse** GW. Round table discussion. Diagnostic criteria in coeliac disease. *Acta Paediatr Scand* 1970; **59**: 461-464 [DOI: 10.1111/j.1651-2227.1970.tb15545.x]

13 **Walker-Smith** JA, Guandalini S, Schmitz J, Shmerling DH, Visakorpi JK. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition. *Arch Dis Child* 1990; **65**: 909-911 [PMID: 2205160 DOI: 10.1136/adc.65.8.909]

14 **Husby S**, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Mäki M, Ribes-Koninckx C, Ventura A, Zimmer KP; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. *J Pediatr Gastroenterol Nutr* 2012; **54**: 136-160 [PMID: 22197856 DOI: 10.1097/MPG.0b013e31821a23d0]

15 **Congia M**, Cucca F, Frau F, Lampis R, Melis L, Clemente MG, Cao A, De Virgiliis S. A gene dosage effect of the DQA1\*0501/DQB1\*0201 allelic combination influences the clinical heterogeneity of celiac disease. *Hum Immunol* 1994; **40**: 138-142 [PMID: 7928444 DOI: 10.1016/0198-8859(94)90059-0]

16 **Herrera M**, Theiler G, Augustovski F, Chertkoff L, Fainboim L, DeRosa S, Cowan EP, Satz ML. Molecular characterization of HLA class II genes in celiac disease patients of Latin American Caucasian origin. *Tissue Antigens* 1994; **43**: 83-87 [PMID: 8016846 DOI: 10.1111/j.1399-0039.1994.tb02305.x]

17 **Fernández-Arquero M**, Polanco I, Escobar H, Figueredo MA, de la Concha EG, Clerici-Larradet N. HLA-DQ alleles and susceptibility to celiac disease in Spanish children. *Tissue Antigens* 1995; **45**: 145-147 [PMID: 7792763 DOI: 10.1111/j.1399-0039.1995.tb02433.x]

18 **Polvi A**, Eland C, Koskimies S, Mäki M, Partanen J. HLA DQ and DP in Finnish families with celiac disease. *Eur J Immunogenet* 1996; **23**: 221-234 [PMID: 8803535 DOI: 10.1111/j.1744-313x.1996.tb00117.x]

19 **Catassi C**, Doloretta Macis M, Rätsch IM, De Virgiliis S, Cucca F. The distribution of DQ genes in the Saharawi population provides only a partial explanation for the high celiac disease prevalence. *Tissue Antigens* 2001; **58**: 402-406 [PMID: 11929591 DOI: 10.1034/j.1399-0039.2001.580609.x]

20 **Kaur G**, Sarkar N, Bhatnagar S, Kumar S, Rapthap CC, Bhan MK, Mehra NK. Pediatric celiac disease in India is associated with multiple DR3-DQ2 haplotypes. *Hum Immunol* 2002; **63**: 677-682 [PMID: 12121676 DOI: 10.1016/s0198-8859(02)00413-5]

21 **Zubillaga P**, Vidales MC, Zubillaga I, Ormaechea V, García-Urkía N, Vitoria JC. HLA-DQA1 and HLA-DQB1 genetic markers and clinical presentation in celiac disease. *J Pediatr Gastroenterol Nutr* 2002; **34**: 548-554 [PMID: 12050583 DOI: 10.1097/00005176-200205000-00014]

22 **Mustalahti K**, Holopainen P, Karell K, Mäki M, Partanen J. Genetic dissection between silent and clinically diagnosed symptomatic forms of coeliac disease in multiplex families. *Dig Liver Dis* 2002; **34**: 842-845 [PMID: 12643291 DOI: 10.1016/s1590-8658(02)80253-5]

23 **Karinen H**, Kärkkäinen P, Pihlajamäki J, Janatuinen E, Heikkinen M, Julkunen R, Kosma VM, Naukkarinen A, Laakso M. HLA genotyping is useful in the evaluation of the risk for coeliac disease in the 1st-degree relatives of patients with coeliac disease. *Scand J Gastroenterol* 2006; **41**: 1299-1304 [PMID: 17060123 DOI: 10.1080/00365520600684548]

24 **Catassi C**, Kryszak D, Louis-Jacques O, Duerksen DR, Hill I, Crowe SE, Brown AR, Procaccini NJ, Wonderly BA, Hartley P, Moreci J, Bennett N, Horvath K, Burk M, Fasano A. Detection of Celiac disease in primary care: a multicenter case-finding study in North America. *Am J Gastroenterol* 2007; **102**: 1454-1460 [PMID: 17355413 DOI: 10.1111/j.1572-0241.2007.01173.x]

25 **Murray JA**, Moore SB, Van Dyke CT, Lahr BD, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd, Kroning CM, El-Yousseff M, Czaja AJ. HLA DQ gene dosage and risk and severity of celiac disease. *Clin Gastroenterol Hepatol* 2007; **5**: 1406-1412 [PMID: 17919990 DOI: 10.1016/j.cgh.2007.08.013]

26 **Dezsofi A**, Szebeni B, Hermann CS, Kapitány A, Veres G, Sipka S, Körner A, Madácsy L, Korponay-Szabó I, Rajczy K, Arató A. Frequencies of genetic polymorphisms of TLR4 and CD14 and of HLA-DQ genotypes in children with celiac disease, type 1 diabetes mellitus, or both. *J Pediatr Gastroenterol Nutr* 2008; **47**: 283-287 [PMID: 18728522 DOI: 10.1097/MPG.0b013e31816de885]

27 **Megiorni F**, Mora B, Bonamico M, Barbato M, Nenna R, Maiella G, Lulli P, Mazzilli MC. HLA-DQ and risk gradient for celiac disease. *Hum Immunol* 2009; **70**: 55-59 [PMID: 19027045 DOI: 10.1016/j.humimm.2008.10.018]

28 **Thomas HJ**, Ahmad T, Rajaguru C, Barnardo M, Warren BF, Jewell DP. Contribution of histological, serological, and genetic factors to the clinical heterogeneity of adult-onset coeliac disease. *Scand J Gastroenterol* 2009; **44**: 1076-1083 [PMID: 19593686 DOI: 10.1080/00365520903100473]

29 **Martins Rde C**, Gandolfi L, Modelli IC, Almeida RC, Castro LC, Pratesi R. Serologic screening and genetic testing among brazilian patients with celiac disease and their first degree relatives. *Arq Gastroenterol* 2010; **47**: 257-262 [PMID: 21140086 DOI: 10.1590/s0004-28032010000300009]

30 **Srivastava A**, Yachha SK, Mathias A, Parveen F, Poddar U, Agrawal S. Prevalence, human leukocyte antigen typing and strategy for screening among Asian first-degree relatives of children with celiac disease. *J Gastroenterol Hepatol* 2010; **25**: 319-324 [PMID: 19929927 DOI: 10.1111/j.1440-1746.2009.06044.x]

31 **El-Akawi ZJ**, Al-Hattab DM, Migdady MA. Frequency of HLA-DQA1\*0501 and DQB1\*0201 alleles in patients with coeliac disease, their first-degree relatives and controls in Jordan. *Ann Trop Paediatr* 2010; **30**: 305-309 [PMID: 21118624 DOI: 10.1179/146532810X12858955921195]

32 **Alarida K**, Harown J, Di Pierro MR, Drago S, Catassi C. HLA-DQ2 and -DQ8 genotypes in celiac and healthy Libyan children. *Dig Liver Dis* 2010; **42**: 425-427 [PMID: 19819768 DOI: 10.1016/j.dld.2009.09.004]

33 **Castro-Antunes MM**, Crovella S, Brandão LA, Guimaraes RL, Motta ME, Silva GA. Frequency distribution of HLA DQ2 and DQ8 in celiac patients and first-degree relatives in Recife, northeastern Brazil. *Clinics (Sao Paulo)* 2011; **66**: 227-231 [PMID: 21484038 DOI: 10.1590/s1807-59322011000200008]

34 **Mubarak A**, Spierings E, Wolters VM, Otten HG, ten Kate FJ, Houwen RH. Children with celiac disease and high tTGA are genetically and phenotypically different. *World J Gastroenterol* 2013; **19**: 7114-7120 [PMID: 24222955 DOI: 10.3748/wjg.v19.i41.7114]

35 **Piccini B**, Vascotto M, Serracca L, Luddi A, Margollicci MA, Balestri P, Vindigni C, Bassotti G, Villanacci V. HLA-DQ typing in the diagnostic algorithm of celiac disease. *Rev Esp Enferm Dig* 2012; **104**: 248-254 [PMID: 22662777 DOI: 10.4321/s1130-01082012000500005]

36 **Krini M**, Chouliaras G, Kanariou M, Varela I, Spanou K, Panayiotou J, Roma E, Constantinidou N. HLA class II high-resolution genotyping in Greek children with celiac disease and impact on disease susceptibility. *Pediatr Res* 2012; **72**: 625-630 [PMID: 23041663 DOI: 10.1038/pr.2012.133]

37 **Fernández-Cavada-Pollo MJ**, Alcalá-Peña MI, Vargas-Pérez ML, Vergara-Prieto E, Vallcorba-Gómez-Del Valle I, Melero-Ruiz J, Márquez-Armenteros AM, Romero-Albillos JA, Narváez-Rodríguez I, Fernández-de-Mera JJ, González-Roiz C. Celiac disease and HLA-DQ genotype: diagnosis of different genetic risk profiles related to the age in Badajoz, southwestern Spain. *Rev Esp Enferm Dig* 2013; **105**: 469-476 [PMID: 24274444 DOI: 10.4321/s1130-01082013000800005]

38 **Delgado JF**, Amengual MJ, Veraguas A, Rodríguez E, de Los Santos MM, Guallarte MP. Paediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes display small clinical differences. *Acta Paediatr* 2014; **103**: e238-e242 [PMID: 24628273 DOI: 10.1111/apa.12605]

39 **Cilleruelo ML**, Roman-Riechmann E, Sanchez-Valverde F, Donat E, Manuel-Ramos J, Martín-Orte E, López MJ, García-Novo D, García S, Pavón P, Martín M, Ortigosa L, Barrio J, Gutierrez C, Espìn B, Castillejo G, Peña-Quintana L, Hualde I, Sebastián M, Calvo C, Fernández S, De Manueles J, Armas H, Urruzuno-Tellerias P, Juste M, Bousoño C, Ribes-Koninckx C. Spanish national registry of celiac disease: incidence and clinical presentation. *J Pediatr Gastroenterol Nutr* 2014; **59**: 522-526 [PMID: 24886992 DOI: 10.1097/MPG.0000000000000446]

40 **Stanković B**, Radlović N, Leković Z, Ristić D, Radlović V, Nikčević G, Kotur N, Vučićević K, Kostić T, Pavlović S, Zukic B. HLA genotyping in pediatric celiac disease patients. *Bosn J Basic Med Sci* 2014; **14**: 171-176 [PMID: 25172978 DOI: 10.17305/bjbms.2014.3.28]

41 **Uenishi RH**, Gandolfi L, Almeida LM, Fritsch PM, Almeida FC, Nóbrega YK, Pratesi R. Screening for celiac disease in 1st degree relatives: a 10-year follow-up study. *BMC Gastroenterol* 2014; **14**: 36 [PMID: 24552206 DOI: 10.1186/1471-230X-14-36]

42 **Oliveira JR**, Cabral AJ, Ferreira E, Capelinha F, Spínola H, Gonçalves R. Celiac disease in children from Madeira island and its prevalence in first degree relatives. *Arq Gastroenterol* 2014; **51**: 151-154 [PMID: 25003269 DOI: 10.1590/s0004-28032014000200015]

43 **Almeida LM**, Gandolfi L, Pratesi R, Uenishi RH, de Almeida FC, Selleski N, Nóbrega YK. Presence of DQ2.2 Associated with DQ2.5 Increases the Risk for Celiac Disease. *Autoimmune Dis* 2016; **2016**: 5409653 [PMID: 28042478 DOI: 10.1155/2016/5409653]

44 **Viken MK**, Flåm ST, Skrivarhaug T, Amundsen SS, Sollid LM, Drivvoll AK, Joner G, Dahl-Jørgensen K, Lie BA. HLA class II alleles in Norwegian patients with coexisting type 1 diabetes and celiac disease. *HLA* 2017; **89**: 278-284 [PMID: 28247576 DOI: 10.1111/tan.12986]

45 **Murad H**, Jazairi B, Khansaa I, Olabi D, Khouri L. HLA-DQ2 and -DQ8 genotype frequency in Syrian celiac disease children: HLA-DQ relative risks evaluation. *BMC Gastroenterol* 2018; **18**: 70 [PMID: 29793442 DOI: 10.1186/s12876-018-0802-2]

46 **Martínez-Ojinaga E**, Fernández-Prieto M, Molina M, Polanco I, Urcelay E, Núñez C. Influence of HLA on clinical and analytical features of pediatric celiac disease. *BMC Gastroenterol* 2019; **19**: 91 [PMID: 31196071 DOI: 10.1186/s12876-019-1014-0]

47 **Poddighe D**, Capittini C, Gaviglio I, Brambilla I, Marseglia GL. HLA-DQB1\*02 allele in children with celiac disease: Potential usefulness for screening strategies. *Int J Immunogenet* 2019; **46**: 342-345 [PMID: 31187602 DOI: 10.1111/iji.12441]

48 **Kauma S**, Kaukinen K, Huhtala H, Kivelä L, Pekki H, Salmi T, Saavalainen P, Lindfors K, Kurppa K. The Phenotype of Celiac Disease Has Low Concordance between Siblings, Despite a Similar Distribution of HLA Haplotypes. *Nutrients* 2019; **11** [PMID: 30823533 DOI: 10.3390/nu11020479]

49 **Sdepanian VL**, Lopes LHC, Oliveira RP, Muniz JG. Celiac Disease in First-degree Relatives: Homozygosity of DQB1\*02 and At Least One Copy of HLA-DQB1\*02 Allele. *J Pediatr Gastroenterol Nutr* 2019; **69**: e149 [PMID: 31425369 DOI: 10.1097/MPG.0000000000002476]

50 **Poddighe D**. HLA-DQB1\*02 Allele in First-degree Relatives of Patients With Celiac Disease. *J Pediatr Gastroenterol Nutr* 2019; **69**: e148-e149 [PMID: 31425368 DOI: 10.1097/MPG.0000000000002475]

51 **Lopes LHC**, Muniz JG, Oliveira RP, Sdepanian VL. Celiac Disease in Brazilian First-degree Relatives: The Odds Are Five Times Greater for HLA DQ2 Homozygous. *J Pediatr Gastroenterol Nutr* 2019; **68**: e77-e80 [PMID: 30601367 DOI: 10.1097/MPG.0000000000002251]

52 **Bajor J**, Szakács Z, Juhász M, Papp M, Kocsis D, Szegedi É, Földi I, Farkas N, Hegyi P, Vincze Á. HLA-DQ2 homozygosis increases tTGA levels at diagnosis but does not influence the clinical phenotype of coeliac disease: A multicentre study. *Int J Immunogenet* 2019; **46**: 74-81 [PMID: 30779476 DOI: 10.1111/iji.12415]

53 **Poddighe D**. Relevance of HLA-DQB1\*02 allele in predisposing to coeliac disease. *Int J Immunogenet* 2019; **46**: 274-275 [PMID: 31001909 DOI: 10.1111/iji.12427]

54 **Bajor J**, Szakács Z, Vincze Á. Response to Letter to the Editor: Relevance of HLA-DQB1\*02 allele in predisposing to coeliac disease. *Int J Immunogenet* 2019; **46**: 276-277 [PMID: 31304681 DOI: 10.1111/iji.12428]

55 **Al-Hussaini A**, Eltayeb-Elsheikh N, Alharthi H, Osman A, Alshahrani M, Sandogji I, Alrashidi S, Bashir MS. HLA-DQ genotypes relative risks for celiac disease in Arabs: A case-control study. *J Dig Dis* 2019; **20**: 602-608 [PMID: 31496112 DOI: 10.1111/1751-2980.12817]

56 **Ramosaj-Morina A**, Burek Kamenaric M, Azemi M, Spahiu L, Grubic Z, Zunec R. HLA Haplotype Association with Celiac Disease in Albanian Pediatric Patients from Kosovo. *Gastroenterol Res Pract* 2019; **2019**: 7369014 [PMID: 31281351 DOI: 10.1155/2019/7369014]

57 **Margaritte-Jeannin P**, Babron MC, Bourgey M, Louka AS, Clot F, Percopo S, Coto I, Hugot JP, Ascher H, Sollid LM, Greco L, Clerget-Darpoux F. HLA-DQ relative risks for coeliac disease in European populations: a study of the European Genetics Cluster on Coeliac Disease. *Tissue Antigens* 2004; **63**: 562-567 [PMID: 15140032 DOI: 10.1111/j.0001-2815.2004.00237.x]

58 **De Silvestri A**, Capittini C, Poddighe D, Valsecchi C, Marseglia G, Tagliacarne SC, Scotti V, Rebuffi C, Pasi A, Martinetti M, Tinelli C. HLA-DQ genetics in children with celiac disease: a meta-analysis suggesting a two-step genetic screening procedure starting with HLA-DQ β chains. *Pediatr Res* 2018; **83**: 564-572 [PMID: 29244800 DOI: 10.1038/pr.2017.307]

59 **Capittini C**, De Silvestri A, Rebuffi C, Tinelli C, Poddighe D. Relevance of HLA-DQB1\*02 Allele in the Genetic Predisposition of Children with Celiac Disease: Additional Cues from a Meta-Analysis. *Medicina (Kaunas)* 2019; **55** [PMID: 31121940 DOI: 10.3390/medicina55050190]

60 **Mejía-León ME**, Ruiz-Dyck KM, Calderón de la Barca AM. HLA-DQ genetic risk gradient for type 1 diabetes and celiac disease in northwestern Mexico. *Rev Gastroenterol Mex* 2015; **80**: 135-143 [PMID: 26088570 DOI: 10.1016/j.rgmx.2015.03.003]

61 **Smigoc Schweiger D**, Mendez A, Kunilo Jamnik S, Bratanic N, Bratina N, Battelino T, Brecelj J, Vidan-Jeras B. High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence of type 1 diabetes and celiac disease. *Autoimmunity* 2016; **49**: 240-247 [PMID: 27138053 DOI: 10.3109/08916934.2016.1164144]

62 **Mitchell RT**, Sun A, Mayo A, Forgan M, Comrie A, Gillett PM. Coeliac screening in a Scottish cohort of children with type 1 diabetes mellitus: is DQ typing the way forward? *Arch Dis Child* 2016; **101**: 230-233 [PMID: 26718815 DOI: 10.1136/archdischild-2015-309754]

63 **Björck S**, Brundin C, Lörinc E, Lynch KF, Agardh D. Screening detects a high proportion of celiac disease in young HLA-genotyped children. *J Pediatr Gastroenterol Nutr* 2010; **50**: 49-53 [PMID: 19915493 DOI: 10.1097/MPG.0b013e3181b477a6]

64 **Franceschini E**, Lionetti ME, D'Adamo G, D'Angelo E, Gatti S, Naspi Catassi G, Malamisura B, Catassi C. Misuse of serological screening tests for celiac disease in children: A prospective study in Italy. *Dig Liver Dis* 2019; **51**: 1547-1550 [PMID: 31383458 DOI: 10.1016/j.dld.2019.06.016]

65 **Ali M**, Danner DJ, Fishman DS, Devaraj S. Utilization of Laboratory Testing Algorithms for Celiac Disease in a Pediatric Hospital. *Lab Med* 2020; **51**: 99-104 [PMID: 31209478 DOI: 10.1093/labmed/lmz037]

66 **Huang Y**, Don-Wauchope AC, Grey VL, Mansour M, Brill H, Armstrong D. Improving serological test ordering patterns for the diagnosis of celiac disease through clinical laboratory audit of practice. *Clin Biochem* 2012; **45**: 455-459 [PMID: 22285379 DOI: 10.1016/j.clinbiochem.2012.01.007]

67 **Mearns ES**, Taylor A, Boulanger T, Craig KJ, Gerber M, Leffler DA, Drahos J, Sanders DS, Lebwohl B. Systematic Literature Review of the Economic Burden of Celiac Disease. *Pharmacoeconomics* 2019; **37**: 45-61 [PMID: 30221333 DOI: 10.1007/s40273-018-0707-5]

68 **Alessandrini S**, Giacomoni E, Muccioli F. Mass population screening for celiac disease in children: the experience in Republic of San Marino from 1993 to 2009. *Ital J Pediatr* 2013; **39**: 67 [PMID: 24152602 DOI: 10.1186/1824-7288-39-67]

69 **Verma AK**, Singh A, Gatti S, Lionetti E, Galeazzi T, Monachesi C, Franceschini E, Ahuja V, Catassi C, Makharia GK. Validation of a novel single-drop rapid human leukocyte antigen-DQ2/-DQ8 typing method to identify subjects susceptible to celiac disease. *JGH Open* 2018; **2**: 311-316 [PMID: 30619943 DOI: 10.1002/jgh3.12090]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**PRISMA 2009 Checklist statement:** The authors prepared the manuscript according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 19, 2019

**First decision:** January 12, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Kazakhstan

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Ciccone MM, Gabriel S, Jadallah KA **S-Editor:** Wang YQ **L-Editor: E-Editor:**

**Figure Legends**



**Figure 1 PRISMA flow-chart of the systematic review.**

**Table 1 Original articles selected and included in this systematic review, *n***

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Total number of CD patients** | **1Age (yr)** | **Sex ratio (M/F)** | **HLA-DQB1\*02 carriers** | **Non-HLA-DQB1\*02 carriers** | **2Notes** | **Clinical** **Background** | **3DM1 patients (< 3%)** |
| Congia *et al*[15], 1994 | Italy | 62 | Group I: 3.08 ± 2.05; Group II: 5.7 ± 3.1 | 24/38 | 61 | 1 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[12] | Symptomatic patients classified as classic (group I) or atypical (group II) CD | + |
| Herrera *et al*[16],1994 | Argentina | 62 | Children | 12/50 | 51 | 2 | HLA-DQ genotyping of 53 patients previously diagnosed with CD (ESPGHAN criteria)[12] | NA. Patients were diagnosed at the gastroenterology unit | ? |
| Fernández-Arquero *et al*[17], 1995 | Spain | 70 | 1.7 (NA) | NA | 67 | 3 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[12] | NA | ? |
| Polvi *et al*[18], 1996 | Finland | 49 | Index cases: 8 (1-34); FDR: NA  | 25/24 | 49 | 0 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | 35 patients diagnosed on a clinical basis (not specified) and 14 FDR diagnosed by case-finding screening | + |
| Catassi *et al*[19], 2001 | Algeria | 79 | 8 (2-37) | 33/44 | 68 | 1 | HLA-DQ genotyping of 69 patients previously diagnosed with CD (confirmed with intestinal biopsy) | NA | ? |
| Kaur *et al*[20], 2002 | India | 35 | 8.42 (1.5-15.6) | 18/17 | 35 | 0 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | Symptomatic patients with consistent GI or extra-GI symptoms | + |
| Zubillaga *et al*[21], 2002 | Spain | 133 | 3.1 (0.5-18) | 59/74 | 132 | 1 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | Patients with classic (71.4%) or non-classic (21.8%) CD. Nine asymptomatic patients diagnosed by case-finding screening (5 FRD, 3 DS, 1 IDDM) | + |
| Mustalahti *et al*[22], 2002 | Finland | 56 | NA | 18/38 | 49 | 0 | HLA-DQ genotyping of symptomatic patients previously diagnosed with CD. Seven patients did not undergo the intestinal biopsy (and, thus, have been excluded) | Twenty-eight symptomatic patients with consistent GI or extra-GI symptoms; and 28 asymptomatic siblings by case-finding screening | + |
| Karinen *et al*[23], 2006 | Finland | 54 | 43.7±14.7 (1-79) | NA | 53 | 1 | HLA-DQ genotyping of patients previously diagnosed with CD (confirmed with intestinal biopsy) | NA (based on clinical symptoms) | + |
| Catassi *et al*[24], 2007 | United States | 22 | (19-83) | 18/4 | 21 | 0 | HLA-DQ genotyping in the context of a multicenter and prospective study (ESPGHAN criteria). HLA-DQ genotyping not done in only one of the 22 new CD diagnoses. | Patients enrollment based on specific GI/extra-GI symptoms; or criteria for case-finding screening. Only 1 CD patients with IDDM | ? |
| Murray *et al* [25], 2007 | United States | 84 | (26-68) | 35/49 | 80 | 4 | HLA-DQ genotyping of patients previously diagnosed with CD (confirmed with intestinal biopsy) | Patients with consistent GI and/or extra-GI symptoms. | + |
| Dezsofi *et al* [26], 2008 | Hungary | 100 | 16 (3-40) | 47/53 | 96 | 4 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA. Anyway, this group was declared as not affected with DM1. | + |
| Megiorni *et al*[27], 2009 | Italy | 437 | 5.7 (NA; only children) | NA | 392 | 45 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | “Patients were divided on the basis of the clinical manifestations and gastrointestinal symptoms in typical, atypical, and silent forms”. No further numerical information is provided and, thus, it cannot be estimated number of IDDM patients | ? |
| Thomas *et al*[28], 2009 | United Kingdom | 384 | 44 (16-84) | 102/282 | 346 | 14 | HLA-DQ genotyping available for 360 patients previously diagnosed with CD (confirmed with intestinal biopsy) | Patients with consistent GI and/or extra-GI symptoms. Only 7 patients were affected with IDDM as well | + |
| Martins *et al*[29], 2010 | Brazil | 90 | 15.5 (1-55) | 35/55 | 84 | 6 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA. Patients were diagnosed at the gastroenterology unit. | ? |
| Srivastava *et al*[30], 2010 | India | 30 | 9.5 (3-17) | 15/16 | 29 | 1 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA. Patients were diagnosed at the gastroenterology unit | ? |
| El-Akawi *et al*[31], 2010 | Jordan | 44 | 13.5 (1-39) | 12/32 | 44 | 0 | HLA-DQ genotyping available for 360 patients previously diagnosed with CD (confirmed with intestinal biopsy) | NA | ? |
| Alarida *et al*[32], 2010 | Libya | 31 | 9.2 (5-18) | 9/22 | 29 | 2 | HLA-DQ genotyping of patients diagnosed with CD (confirmed with intestinal biopsy) | School children undergone mass screening through anti-TG IgA | ? |
| Castro-Antunes *et al*[33], 2011 | Brazil | 73 | NA (children and adults) | 37/36 | 60 | 13 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13]; One patient did not undergo HLA analysis | Patients enrollment based on specific GI/extra-GI symptoms; or criteria for case-finding screening (15: FDR or IDDM, whose proportion is not specified) | - |
| Mubarak *et al*[34], 2012 | the Netherlands | 70 | 5.7 (NA; only children) | 20/50 | 70 | 0 | HLA-DQ genotyping of patients diagnosed with CD (confirmed with intestinal biopsy) | NA | ? |
| Mubarak *et al*[34], 2012 | the Netherlands | 85 | 6.2 (NA; only children) | 25/60 | 81 | 4 | HLA-DQ genotyping performed in all consecutive CD patients (confirmed with intestinal biopsy) at the time of the diagnosis | NA | ? |
| Piccini *et al*[35], 2012 | Italy | 89 | NA (< 18) | 27/62 | 81 | 8 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA | ? |
| Krini *et al*[36], 2012 | Greece | 118 | NA (< 18) | NA | 105 | 13 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA | ? |
| Fernández-Cavada-Pollo *et al*[37], 2013 | Spain | 355 | NA (0.5-76; children: *n* = 214, adults: *n* = 141) | NA | 335 | 20 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | Patients with consistent GI and/or extra-GI symptoms | + |
| Delgado *et al*[38], 2014 | Spain | 91 | 6.9 (NA; only children) | 23/68 | 88 | 3 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[14] | Patients with consistent GI and/or extra-GI symptoms; or with an affected FDR | + |
| Cilleruelo *et al*[39], 2014 | Spain | 513 | NA (0.5-15) | NA | 496 | 17 | HLA-DQ genotyping in the context of a multicenter and prospective study (ESPGHAN criteria)[13] | Patients enrollment based on classic or atypical symptoms consistent with CD; or criteria for case-finding screening. IDDM is reported in 2.2% (*n* = 11) of CD patients | + |
| Stanković *et al*[40], 2014 | Serbia | 73 | 12 (1-22) | 19/54 | 71 | 2 | HLA-DQ genotyping in the context of a multicenter and prospective study (ESPGHAN criteria)[13] | NA | ? |
| Uenishi *et al*[41], 2014 | Brazil | 5 | NA (7-75) | 1/4 | 5 | 0 | HLA-DQ genotyping of patients diagnosed with CD (confirmed with intestinal biopsy) | FDR case-finding screening | + |
| Oliveira *et al*[42], 2014 | Portugal | 39 | 1.8 (0.5-17) | 18/21 | 37 | 1 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[14].One patient did not undergo HLA typing | Patients with consistent GI and/or extra-GI symptoms. | + |
| Almeida *et al*[43], 2016 | Brazil | 237 | 22 (1-75) | 73/164 | 222 | 15 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA | ? |
| Viken *et al*[44], 2017 | Norway | 327 | NA (both children andadults) | NA | 310 | 17 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | NA. Patients with IDDM have been excluded.  | + |
| Murad *et al*[45], 2018 | Syria | 49 | 9.5 (1-18) | 14/35 | 45 | 4 | HLA-DQ genotyping of patients diagnosed with CD (confirmed with intestinal biopsy) | NA | ? |
| Martínez-Ojinaga *et al*[46], 2019 | Spain | 463 | 2.6 (0.6-14) | NANA | 454 | 9 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13,14] | Patients with consistent GI/extra-GI symptoms; or criteria for case-finding screening (not specified) | + |
| Poddighe *et al*[47], 2019 | Italy | 184 | NA (1-16) | 70/114 | 179 | 5 | HLA-DQ genotyping of 184 patients previously diagnosed with CD (ESPGHAN criteria)[13,14] | Patients with consistent GI (*n* = 75) or extra-GI (*n* = 69) symptoms; or criteria for case-finding screening (*n* = 40) | + |
| Kauma *et al*[48], 2019 | Finland | 100 | 3.08 ± 2.05 (CD index cases) | 19/81 | 64 | 2 | HLA-DQ genotyping was available for 132 patients diagnosed with CD (confirmed with intestinal biopsy) in the context of a research study considering pairs of siblings both affected with CD | Patients with consistent GI/extra-GI symptoms. There is only one patient with IDDM among CD index cases | + |
| Kauma *et al*[48], 2019 | Finland | 100 | CD siblings5.7 ± 3.1 | 37/63NA | 59 | 7 | See previous notes (same study/article) | Patients with consistent GI/extra-GI symptoms. There are 4 patients with IDDM among sibling CD cases | - |
| 4Lopes *et al*[49-51], 2019 | Brazil | 7 | 7.5 (6-12) | NA | 7 | 0 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13] | FDR case-finding screening. 7 CD cases out of 114 screened FDR | + |
| 4Bajor *et al*[52-54], 2019 | Hungary | 105 | 31.2 (0.5-78) | 32/73 | 97 | 8 | HLA-DQ genotyping of patients diagnosed with CD (confirmed with intestinal biopsy) | Patients with consistent GI or extra-GI symptoms; or criteria for case-finding screening. No CD patients with IDDM | + |
| Al-Hussaini *et al*[55], 2019 | Saudi Arabia | 100 | Group 1: 7 ± 3.2 | 19/27 | 43 | 3 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13,14] | Patients with consistent GI or extra-GI symptoms (Group 1, *n* = 46). No data about comorbidity (*e.g.* IDDM) | + |
| Al-Hussaini *et al*[55], 2019 | Saudi Arabia | 100 | Group 2: 11.3 ± 2.5 | 11/43 | 45 | 9 | Refer to the previous notes (same study/ article) | Patients diagnosed through a mass screening among school children (Group 2, *n* = 54). No data about comorbidity (*e.g.* IDDM) | - |
| Ramosaj-Morina *et al*[56], 2019 | Kosovo | 60 | 5.5 (1.5-18) | 20/40 | 55 | 5 | HLA-DQ genotyping of patients previously diagnosed with CD (ESPGHAN criteria)[13,14] | NA | ? |

1This column describe the age of the patients, in terms of mean± SD or median (age range); 2This column describes the version of ESPGHAN guidelines that each article refers to, if provided: If a superscript number is present, it refers to the specific reference. Anyway, all articles included in this systematic review based the final celiac disease (CD) diagnosis on the duodenal biopsy, even if no specific guidelines are reported in the original article (in this case, no superscript number is present); 3This column assesses the presence of patients affected with type 1 diabetes mellitus (DM1) in the population of CD patients included in the respective article (+: it indicates that the study includes or is estimated to include < 3% of CD patients with DM1; ?: it indicates that the article provided no data to estimate the actual percentage of CD patients affected with DM1; -: it indicates that the study clearly indicates the number of CD patients with DM1 and those are at least 3% of the study cohort); 4These articles have been completed with additional references, in order to provide all necessary information about the HLA-DQB1\*02 carrier status in the CD patients included in the respective studies. CD: Celiac disease; DM1: Type 1 diabetes mellitus; FDR: First degree relative; TG: Transglutaminase; NA: Not available.